Search clinical trials for: Maraviroc Boceprevir

Total 214 results

ViiV Healthcare
Pfizer

Completed

Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

Healthy

Belgium
Centre hospitalier de l'Université de Montréal...
McGill University Health Centre/Research Institute of the McGill University... and other collaborators

Completed

The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers

Healthy

Canada
Merck Sharp & Dohme LLC

Completed

Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)

Hepatitis C
Merck Sharp & Dohme LLC

Terminated

Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)

Hepatitis C, Chronic
Indiana University
Merck Sharp & Dohme LLC

Completed

Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation

Liver Transplantation

United States
Erasmus Medical Center
Radboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaborators

Completed

Dutch Acute HCV in HIV Study (DAHHS) (DAHHS)

Hepatitis C | Human Immunodeficiency Virus

Netherlands
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)

Hepatitis C, Chronic
St Stephens Aids Trust
University of Turin, Italy; University of Liverpool

Completed

Boceprevir and Ucalm (St John&Apos;s Wort)

Hepatitis C

United Kingdom
GlaxoSmithKline

Completed

Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects

Thrombocytopaenia

United States
Arrowhead Regional Medical Center

Terminated

Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

Hepatitis C Infection

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation

Hematopoietic Stem Cell Transplantation | Graft-versus-host Disease
ViiV Healthcare
Pfizer

No longer available

A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India

Human Immunodeficiency Virus (HIV)
University of Calgary
Merck Sharp & Dohme LLC

Completed

Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment (LeeG3)

Hepatitis C

Canada
Kirby Institute

Completed

MARCH Vascular Endothelium Substudy (MARCH VE)

Cardiovascular Disease

Argentina, Australia, Germany, Thailand
International Partnership for Microbicides, Inc.

Withdrawn

A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium

HIV Infections
International Partnership for Microbicides, Inc.
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Completed

Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults

HIV/AIDS

United States
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)

Chronic Hepatitis C
International Partnership for Microbicides, Inc.

Completed

Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring

HIV Infections

United States
St Stephens Aids Trust

Completed

A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study (CINAMMON)

HIV

United Kingdom
Hoffmann-La Roche

Completed

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

France, United States, Canada, Germany, Spain, Italy, Puerto Rico
Hu Tsung-Hui

Unknown

Boceprevir Treatment in Liver Pre-transplant HCV Patients

Late Complication From Liver Transplant

Taiwan
University of Modena and Reggio Emilia
Merck Sharp & Dohme LLC

Unknown

Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC) (MEN_BOC)

Menopause | Chronic Hepatitis C

Italy
University of Maryland, Baltimore
Merck Sharp & Dohme LLC

Completed

R5 Integrase Study in HIV-1 Naive Patients

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

HIV Infections

United States, Puerto Rico, Thailand, South Africa, Brazil
Emory University

Completed

Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women (MVC-PREP)

HIV

United States
French National Agency for Research on AIDS and...
Pfizer

Completed

Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration (145 MARIMUNO)

HIV Infections | HIV Infection

France
University Of Perugia

Completed

Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.

Inflammation | Atherosclerosis | Cardiovascular Risk Factor | HIV Infection With Other Conditions

Italy
Germans Trias i Pujol Hospital

Completed

Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

HIV Infections | HIV

Spain
ViiV Healthcare
Pfizer

Completed

Prospective Observational Epidemiologic Study of Maraviroc's Safety (POEM)

Human Immunodeficiency Virus

United States, Canada, Spain, Belgium, France, United Kingdom, Italy, Brazil, Puerto Rico, Germany, Greece
ViiV Healthcare

Completed

Expanded Access Program for Maraviroc At Multiple Centers

HIV Infections

Canada, United States, Spain, Switzerland, Malaysia, France, Italy, Portugal, Puerto Rico, Mexico, Australia, Ireland, Romania, Greece, United Kingdom, Argentina, Austria, Belgium, Chile, Costa Rica, Dominican Republic, Germany, Hong... and more
University of Hawaii
Pfizer

Completed

Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

HIV Infections

United States
Fundación Pública Andaluza para la gestión de la...

Completed

Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) (COVIMAR)

Virus Diseases

Spain
ViiV Healthcare
Pfizer

Completed

Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection

HIV-1
University of California, San Francisco
Pfizer; Stanford University; amfAR, The Foundation for AIDS Research; Case Western... and other collaborators

Completed

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

HIV Infection

United States
ANRS, Emerging Infectious Diseases
Pfizer

Completed

Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients (OPTIMAL)

HIV-1 Infection | AIDS

France
S.F.L. van Lelyveld
Pfizer; Erasmus Medical Center; Academisch Medisch Centrum - Universiteit van... and other collaborators

Completed

Maraviroc Immune Recovery Study (MIRS)

HIV Infections

Netherlands
Asociacion para el Estudio de las Enfermedades...

Completed

Double-method Comparative Study in Order to Predict the Use of Co-receptors From Type 1 HIV: Phenotypic Study (Trofile ESTA®) and Virologic Response to a CCR5 Antagonist in the Short Term (TROPISMVC)

HIV Infections

Spain
Tel-Aviv Sourasky Medical Center

Completed

Safety of Maraviroc for Post-stroke Depression (MRV-PSD)

Post-stroke Depression

Israel
ViiV Healthcare
Pfizer; Copenhagen HIV Programme

Completed

EuroSIDA As An External Comparator To MOTIVATE Trials

HIV | AIDS
ViiV Healthcare
Pfizer

Completed

Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers

Human Immunodeficiency Virus (HIV) Infection

Singapore
Hospital Universitario Infanta Leonor
Hospital Clinic of Barcelona; ViiV Healthcare

Terminated

Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19). (MARACOVID)

COVID-19

Spain
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects (MOTIVATE 2)

HIV Infections

Netherlands, United States, Italy, Spain, United Kingdom, France, Germany, Australia, Switzerland, Belgium, Canada, Poland, Sweden
ViiV Healthcare
Pfizer

Completed

Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

HIV

United States, United Kingdom, Germany
ViiV Healthcare
Pfizer

Completed

Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

HIV Infections

Netherlands, Germany, United Kingdom
ViiV Healthcare
Pfizer

Terminated

Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay

HIV Infections

United States, Canada
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects

HIV Infections

Canada, United States, United Kingdom, Netherlands, Australia, Germany, Spain, Belgium, Switzerland
Kevin F. Gibson
University of Pittsburgh

Terminated

Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes (GRADS)

Sarcoidosis

United States
Merck Sharp & Dohme LLC

Completed

Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)

Hepatitis C, Chronic
ViiV Healthcare
Pfizer

Completed

Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)

CCR5-tropic HIV-1 Infection
ASST Fatebenefratelli Sacco

Completed

Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects

HIV Infections

Italy

Search clinical trials for: Maraviroc Boceprevir

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations